Abstract 1247P
Background
Volatile organic compounds (VOCs) are known to be associated with lung cancer, and EGFR mutations are common in lung adenocarcinoma. In this study, we aimed to investigate the potential of VOCs analysis as a non-invasive method for early detection of EGFR mutation.
Methods
We collected breath samples from 114 EGFR wild-type lung adenocarcinoma patients and 132 EGFR mutant lung adenocarcinoma patients and analyzed them using High-Pressure Photon Ionization Time-of-Flight Mass Spectrometry (HPPl-TOFMS) to detect VOCs. A detection model for EGFR mutation based on VOC analysis was established using the eXtreme Gradient Boosting (XGB) algorithm. For building the EGFR mutation detection model, all the samples were randomly split into a training set, validation set, and test set with a ratio of 5:2:3.
Results
The top ten VOC ions which were significantly different between the EGFR mutant lung adenocarcinoma patients and patients without EGFR mutation were displayed in the table (P < 0.05). The discrimination power of each VOC was relatively limited. Among them, 2-Ethyl-4,5-dimethylthiazole had the highest accuracy with an area under the receiver operating characteristic curve (AUC) of 0.829 (95%CI: 0.744-0.974). With the combination of these 10 VOC ions, the model performs well. The AUC for the combination model was 0.895 (95% CI: 0.810-0.980) in the validation cohort, while the AUC in the test set was 0.849 (95% CI: 0.769-0.930), indicating good diagnostic accuracy, with sensitivity and specificity of 70.7% (95% CI: 56.6%, 84.4%) and 71.4% (95% CI: 56.2%, 86.6%). Table: 1247P
The top 10 VOC ions related to EGFR mutation in lung adenocarcinoma
Chemicals | Peak area | P-value | |
EGFR mut | RGFR wild | ||
Cyclohexanone oxime | 242.6±103.4 | 139.1±234.1 | <0.001 |
Dimethoxybenzene | 522.7±1730.2 | 200.0±256.6 | 0.017 |
Tert-Butyl methyl ether | 667.5±1655.3 | 278.4±302.0 | 0.006 |
2-Ethyl-4,5-dimethylthiazole | 659.0±1762.2 | 329.7±730.8 | 0.039 |
Trimethylbenzene | 375.1±617.7 | 202.9±185.6 | <0.001 |
Salicylamide | 310.6±332.9 | 203.0±187.3 | <0.001 |
p-cymene/Cinnamyl alcohol | 300.5±1002.5 | 123.5±130.7 | 0.038 |
L-serine/D-serine | 706.2±515.0 | 359.9±318.0 | <0.001 |
1-Propanethiol | 2005.3±1609.7 | 1419.7±1673.0 | 0.002 |
4-Methylanisole/2-Methylanisole | 402.1±314.4 | 180.1±220.1 | <0.001 |
Conclusions
Our study suggested that VOCs analysis might be useful as non-invasive methods for early detection of EGFR mutations in lung adenocarcinoma. Further studies are needed to validate the accuracy of our model.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The Chinese National Natural Science Foundation Project; China Postdoctoral Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1774P - PC-PEP, a comprehensive daily six-month home-based prostate cancer: Patient empowerment program improves quality of life, physical fitness, and urinary function outcomes among prostate cancer patients with localized disease - Secondary analyses of a randomized clinical trial
Presenter: Gabriela Ilie
Session: Poster session 14
1775P - A newly-developed deep-learning algorithm: NAFNet outperforms ResNet50 for predicting adverse pathology events and biochemical recurrence time using MRI from prostate cancer patients
Presenter: Zheng Liu
Session: Poster session 14
1776P - Body composition in adult life and prostate cancer (PCa) incidence and mortality: The PROCA-life study
Presenter: Martin Støyten
Session: Poster session 14
1777P - Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints
Presenter: Ugo De Giorgi
Session: Poster session 14
1778P - Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK
Presenter: Stephen Freedland
Session: Poster session 14
1779P - PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial
Presenter: Giulio Francolini
Session: Poster session 14
1780P - The health inequality impact of darolutamide for non-metastatic castration-resistant prostate cancer: A distributional cost-effectiveness analysis
Presenter: Jeroen Jansen
Session: Poster session 14
1782P - Prostate radiotherapy reduces long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer (mHSPC): Results from the STAMPEDE M1|RT comparison
Presenter: Craig Jones
Session: Poster session 14
1783P - PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14